Publications

Shaw J, Hsu H, Tu H, Chia V, Aggarwal S, Carrigan G, Kelsh MA. Immortal time bias impacts time-to-time event outcomes in cohort with genomic testing. Abstract 6F-03, International Society for Pharmacoepidemiology (ISPE) 41^st Annual Meeting, Washington, DC, August 2025.

Sidhu MK, Miller B, Jensen I, Rabiner P. 2025. Abstract EE171: Conceptual framework for a de novo cost-effectiveness model in glycogen storage disease type Ia (GSDIa). Value in Health 28(6-Sup1):S93-S94; doi: 10.1016/j.jval.2025.04.463.

Price M, Suh M, Pastula S, Kruchko C, Ostrom Q. Pediatric low-grade glioma (pLGG) incidence in the United States from 2015 through 2019. Abstract LGG-04, Society for NeuroOncology (SNO) Pediatric Neuro-Oncology Conference, San Diego, CA, May 2025.

Desai NR, Piccini JP, Sacks NC, Reichert H, Hooda N, Jiang X, Blood AJ, Holz A, et al. Emergency department visits and inpatient admissions for atrial fibrillation in the United States (US): 2015-2019. Abstract I10, Academy of Managed Care Pharmacy (AMCP) Annual Meeting. J Manag Care Spec Pharm 31(3-a Suppl):S74; doi: 10.18553/jmcp.2025.31.3-a.s1. Houston, TX, March 31-April 3, 2025.

Tao C, Nicholson G, Desai N, Sacks N, Sherwood R, Pokorney S. Budget impact of etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States. Abstract I9, AMCP Annual Meeting. J Manag Care Spec Pharm 31(3-a Suppl):S73; doi: 10.18553/jmcp.2025.31.3-a.s1. Houston, TX, March 21-April 3, 2025.

Haselkorn T, Hughes W, Schara-Schmidt U, Lennox A, Roca A, Miller B, Jensen I, Solomon F, et al. 2024. Abstract PCR257: Real-world impact of x-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Value in Health 27(12-Sup):S557; doi: 10.1016/j.val.2024.10.3499.

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024. Value in Health 27(12 Sup):S191; doi: 10.1016/j.jval.2024.10.973. Barcelona, November 2024.

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. The cost-effectiveness of atidarsagene autotemcel (ARSACEL) for the treatment of metachromatic leukodystrophy (MLD) in Spain. ISPOR Europe 2024, November 2024.

Haselkorn T, Roca A, Miller B, Jensen I, Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, Valencia, Spain, 19–23 November 2024.

Suh M, Mittal L, Brorby G, Pastula S, Vincent M, Proctor D. Epidemiology is critical in advancing cumulative impact assessment (CIA) research: A pilot study in San Antonio, Texas. International Society of Exposure Science, Montreal, Canada, October 2024.